- Conditions
- Mixed Lineage Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoid Leukemia
- Interventions
- Bortezomib, Vorinostat, Mitoxantrone, Cytarabine, Methotrexate, Hydrocortisone, Peg-L-Asparaginase, Erwinia L-Asparaginase, Dexamethasone, Mercaptopurine, Doxorubicin
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 90
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Venetoclax, Cytarabine, Idarubicin, Intrathecal Triple Therapy, Azacitidine
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 2 Years to 20 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Chapel Hill, North Carolina • Memphis, Tennessee
- Conditions
- Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood
- Interventions
- Azacytidine, Fludarabine, Cytarabine, Intrathecal (IT) Cytarabine, Intrathecal Methotrexate (IT MTX)
- Drug
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 19
- States / cities
- Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 16 more
- Conditions
- Leukemia
- Interventions
- anti-thymocyte globulin, asparaginase, busulfan, cyclophosphamide, cyclosporine, cytarabine, daunorubicin hydrochloride, etoposide, leucovorin calcium, melphalan, mercaptopurine, methotrexate, mitoxantrone hydrochloride, pegaspargase, prednisolone, prednisone, therapeutic hydrocortisone, thioguanine, vincristine sulfate, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Dutch Childhood Oncology Group
- Other
- Eligibility
- Up to 1 Year
- Enrollment
- 445 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Memphis, Tennessee • Houston, Texas + 1 more
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Selinexor, Fludarabine, Cytarabine, methotrexate/hydrocortisone/cytarabine
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 24 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Palo Alto, California • Chicago, Illinois + 4 more
- Conditions
- B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome
- Interventions
- Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Mercaptopurine Oral Suspension, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
- Drug · Biological · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 365 Days to 31 Years
- Enrollment
- 6,720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 201
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
- Conditions
- Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, T Cell, Leukemia, Lymphoblastic, Acute
- Interventions
- EZN-3042, Cytarabine, Doxorubicin, Prednisone, Vincristine, PEG-asparaginase, Methotrexate, Hydrocortisone
- Drug
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 2 more
- Conditions
- Leukemia
- Interventions
- filgrastim, asparaginase, cyclophosphamide, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, liposomal cytarabine, mercaptopurine, mesna, methotrexate, therapeutic hydrocortisone, thiotepa, vincristine sulfate, low-LET electron therapy, low-LET photon therapy
- Biological · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 20 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1996
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 48 more
- Conditions
- Acute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma
- Interventions
- DNR, VCR, PEG-asp, CTX, Prednisone, Liposomal AraC, MTX, LCV, AraC, Etoposide, Dasatinib, Rituximab, Hydrocortisone
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 4
- States / cities
- La Jolla, California • Los Angeles, California • Sacramento, California + 1 more
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Mitoxantrone, Mitoxantrone Hydrochloride, Pegaspargase, Pharmacological Study, Radiation Therapy, Therapeutic Hydrocortisone, Thioguanine, Vincristine, Vincristine Sulfate
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 31 Years
- Enrollment
- 669 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 166
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 135 more
- Conditions
- Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Laboratory Biomarker Analysis, Leucovorin Calcium, Levoleucovorin, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Questionnaire Administration, Therapeutic Hydrocortisone, Thioguanine, Vincristine Sulfate
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 352 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 184
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 145 more
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS), Mixed Phenotype Acute Leukemia (MPAL)
- Interventions
- Selinexor, Fludarabine, Cytarabine, methotrexate/hydrocortisone/cytarabine
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 24 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Palo Alto, California • Chicago, Illinois + 3 more
- Conditions
- Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Recurrent Juvenile Myelomonocytic Leukemia, Refractory Childhood Acute Myeloid Leukemia, Refractory Childhood Myelodysplastic Syndrome, Refractory Juvenile Myelomonocytic Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cytarabine, Echocardiography Test, Fludarabine, Hydrocortisone Sodium Succinate, Imetelstat, Leucovorin Calcium, Lumbar Puncture, Methotrexate
- Procedure · Drug · Biological
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 16 more
- Conditions
- Central Nervous System Tumor, Pediatric
- Interventions
- filgrastim, cisplatin, cyclophosphamide, cytarabine, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, leucovorin calcium, methotrexate, temozolomide, therapeutic hydrocortisone, vincristine sulfate, radiation therapy, Dactinomycin
- Biological · Drug · Radiation
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 12
- States / cities
- Stanford, California • New Haven, Connecticut • Atlanta, Georgia + 8 more
- Conditions
- Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia
- Interventions
- Tagraxofusp, Fludarabine, Cytarabine, Dexamethasone, Vincristine, Azacitidine, Methotrexate, Cytarabine IT, Hydrocortisone
- Drug
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 29
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 25 more
- Conditions
- Leukemia
- Interventions
- aldesleukin, filgrastim, therapeutic allogeneic lymphocytes, cytarabine, etoposide, fludarabine phosphate, methotrexate, mitoxantrone hydrochloride, therapeutic hydrocortisone, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2005
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Anaplastic Large Cell Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma
- Interventions
- monoclonal antibody SGN-30, therapeutic hydrocortisone, ifosfamide, carboplatin, etoposide, methotrexate, cytarabine, pharmacological study, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Lymphoblastic Leukemia, Pediatric
- Interventions
- Pegaspargase, Erwinia asparaginase, Cyclophosphamide, CYTARABINE, DASATINIB, DEXAMETHASONE, Dexrazoxane, Doxorubicin, ETOPOSIDE, HYDROCORTISONE, LEUCOVORIN CALCIUM, MERCAPTOPURINE, METHOTREXATE, NELARABINE, Vincristine
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2034
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • New Brunswick, New Jersey • Buffalo, New York + 3 more
- Conditions
- B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia
- Interventions
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Pegaspargase, Positron Emission Tomography, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, Thioguanine, Vincristine Sulfate
- Procedure · Biological · Drug + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 365 Days to 25 Years
- Enrollment
- 5,951 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2032
- U.S. locations
- 203
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 155 more
- Conditions
- Leukemia, Lymphoma
- Interventions
- cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, mesna, methotrexate, prednisone, therapeutic hydrocortisone, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy
- Drug · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 2006
- U.S. locations
- 23
- States / cities
- La Jolla, California • San Francisco, California • Wilmington, Delaware + 18 more
- Conditions
- Acute Leukemia of Ambiguous Lineage in Relapse, Acute Myeloid Leukemia, in Relapse, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia
- Interventions
- Venetoclax, Selinexor, Cytarabine, Fludarabine, Filgrastim, Methotrexate, methotrexate/hydrocortisone/cytarabine
- Drug · Biological
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 2 Years to 30 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 8
- States / cities
- San Diego, California • Boston, Massachusetts • New York, New York + 5 more
- Conditions
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Interventions
- L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone, vincristine sulfate, epratuzumab, cytarabine, prednisone, pegaspargase, dexrazoxane hydrochloride, methotrexate, etoposide, cyclophosphamide, leucovorin calcium, filgrastim
- Drug · Biological
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 2 Years to 31 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Loma Linda, California • Long Beach, California + 36 more
- Conditions
- Leukemia, Lymphocytic, Lymphoblastic Lymphoma, T-cell Lymphoma, T-cell Leukemia, Recurrent Disease, Acute Leukemia
- Interventions
- Palbociclib, Cytarabine, Methotrexate, Hydrocortisone, Doxorubicin, Prednisolone, Vincristine, Pegaspargase, Prednisone
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 12 Months to 31 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Loma Linda, California • Orange, California + 15 more
- Conditions
- Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Calaspargase Pegol, Cytarabine, Dexamethasone, Hydrocortisone Sodium Succinate, Lumbar Puncture, Mercaptopurine, Methotrexate, Nivolumab, Pegaspargase, Vincristine Sulfate
- Radiation · Drug · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 461 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 211
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 151 more